Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity

The Associate Director, US Compliance, Field Commercialization, reporting to the Sr. Director, Compliance, will serve aas a primary compliance business partner in support of the company’s planned US commercialization activities for non-small cell lung cancer (NSCLC). The Associate Director is responsible for executing and managing the compliance strategy and program for NSCLC field organizations across Commercial and Medical. This role serves as a trusted compliance business partner to a range of business functions, providing actionable compliance guidance that enables compliant execution while advancing organizational objectives.

The Associate Director will lead the development, implementation, and continuous enhancement of a comprehensive field compliance program, embedding compliance into field operations and supporting the company's growth. This role will proactively identify compliance risks, develop scalable solutions, and influence business decisions across a dynamic and evolving commercialization environment.

Essential Duties and Responsibilities include:

The Associate Director will collaborate and build strong partnerships with several cross-functional stakeholders to help enable commercialization and growth within the NSCLC space. Areas of focus include:

Field Compliance Leadership

Serve as a compliance business partner for field organizations, including Sales, Marketing, Medical Affairs, Patient Services, and other functions.

Provide strategic and actionable compliance guidance regarding field execution, emerging risks, and business initiatives.

Lead the identification, assessment, and mitigation of compliance risks associated with field activities and commercialization efforts.

Develop and implement scalable compliance solutions that support evolving business needs and product launches.

Field Training & Communication

Execute on the strategy, design, and governance of field compliance training programs across field-facing NSCLC teams.

Develop risk-based training plans informed by business activities, monitoring insights, audit findings, industry trends, enforcement actions, and regulatory developments.

Serve as a presenter and facilitator for compliance training at national sales meetings, launch meetings, leadership forums, and onboarding programs.

Evaluate training effectiveness through metrics, feedback, and monitoring results and implement continuous improvements.

Policies, SOPs, and Governance

Assist with the development, implementation, and governance of policies, SOPs, standards, and guidance impacting field-facing NSCLC activities.

Working with the broader Compliance team, ensure compliance policies and procedures remain current with evolving regulatory requirements, industry standards, and business needs.

Drive cross-functional governance initiatives and facilitate alignment among Compliance, Legal, and business stakeholders.

Establish practical frameworks, job aids, and guidance documents that enable consistent and compliant field execution to ensure teams successfully navigate the compliance landscape.

Auditing, Monitoring & Risk Management

Execute field-related monitoring activities with the broader Compliance team.

Analyze monitoring trends and audit results to identify systemic risks, root causes, and opportunities for process improvement.